The Latest
-
Adeline Kon / BioPharma Dive/BioPharma Dive
Deep Dive // Patent thicketsDrug patents protect pharma profits. Track when they’ll expire here.
Intellectual property is the foundation of the drug industry’s business model. This database will track key patent expiry dates for 30 top-selling medicines.
Updated May 13, 2024 -
Phynart Studio via Getty Images
Sponsored by PearsonAcknowledging comorbidities in trial design is essential for successful outcomes
Examine why adaptive trials that consider comorbidities are critical for a successful trial outcome.
-
Courtesy of AbbVie
Biosimilars are gaining ground. The IRA could push them further next year.
As commercial momentum builds, coverage incentives for the Medicare market are expected to favor biosimilars in 2025.
-
Courtesy of Sanofi
Sanofi gambles $80M on Fulcrum’s muscular dystrophy drug
The deal gives the pharma partial rights to a medicine GSK once developed for heart disease but could soon become the first therapy for facioscapulohumeral muscular dystrophy.
-
Stock via Getty Images
Takeda targets ‘efficiency’ in restructuring, pipeline cuts
Among the pipeline changes is a decision by Takeda to terminate studies in blood cancer of TAK-007, a CAR-NK therapy, and to pivot instead to autoimmune conditions.
Updated May 10, 2024 -
Permission granted by Maze Therapeutics
Maze lands new partner for Pompe drug, after Sanofi pact came apart
An alliance with Shionogi involves similar terms as a deal Sanofi canceled in response to an unusual challenge from the Federal Trade Commission.
-
Carsten Koall via Getty Images
Novavax gets a lifeline with Sanofi vaccine pact
Sanofi will ally with the under-pressure biotech, paying $500 million upfront for rights to co-commercialize Novavax’s COVID shot and develop combination influenza vaccines.
-
Adeline Kon/BioPharma Dive
Deep DiveBiotech M&A is on the upswing. Track the latest deals here.
Mariana Oncology’s sale to Novartis is the latest acquisition in a $9 billion deal streak involving developers of radiopharmaceutical drugs for cancer.
Updated May 2, 2024 -
Maddie Meyer via Getty Images
RSV vaccinesFDA delays decision on Moderna RSV vaccine
The regulator cited “administrative constraints,” rather than any issue with Moderna’s trial data, for missing a May 12 deadline, the company said.
-
Daniel Tadevosyan via Getty Images
News roundupiTeos shares jump on TIGIT update; Acelyrin swaps CEOs
Interim data surpassed expectations, iTeos said. Elsewhere, Acelyrin revealed chief executive officer Shao-Lee Lin is departing and Bluebird bio gave a fuller account of its gene therapy launches.
-
Courtesy of Sanofi
Royalty Pharma pays startup $525M for stake in Sanofi MS drug
The deal gives the company milestone payments and royalties to a medicine, frexalimab, that Sanofi licensed from biotech ImmuNext and expects to be a future blockbuster.
-
Courtesy of Novo Nordisk
Obesity drugsNovo taps another Flagship startup in search for next obesity drugs
The deal with Metaphore Biotechnologies is the third from a Flagship alliance meant to boost the Danish drugmaker’s pipeline of weight loss medicines.
-
libre de droit via Getty Images
Regeneron gene therapy improves hearing in two children
The results add to an early but growing body of evidence suggesting gene therapy may improve outcomes in young kids with a genetic form of deafness.
Updated May 8, 2024 -
Sean Gallup via Getty Images
AstraZeneca withdraws COVID-19 vaccine, citing declining demand
The move ends a turbulent saga for AstraZeneca, which successfully developed a coronavirus shot but struggled to sell it amid competition and the emergence of rare but serious side effects.
-
David Dee Delgado via Getty Images
Patient dies in Pfizer study of Duchenne gene therapy
Pfizer said the patient, a young boy who was treated earlier last year, died suddenly from cardiac arrest. The company is working with trial researchers to investigate further.
Updated May 8, 2024 -
Jacob Bell / BioPharma Dive
New Alzheimer's drugsFDA sets date for advisory meeting on Lilly’s closely watched Alzheimer’s drug
After delaying an approval decision for Lilly’s donanemab, the agency now intends to hold an advisory committee meeting on June 10.
-
Seth Babin/BioPharma Dive
Gene editingVerve moves forward with backup base editing therapy
Weeks after a safety setback derailed its lead candidate, the company has treated the first participant in a trial of its heart disease treatment Verve-102.
-
Permission granted by Prologue Medicines
Emerging biotechPrologue, Flagship’s newest startup, looks to mine viruses for new drugs
The company is using what it claims is the largest database of viral protein structures to unearth medicines for a range of diseases, said CEO and Flagship origination partner Lovisa Afzelius.
-
Love Employee via Getty Images
Zenas, with new funding, aims dual-targeting antibody at lupus and MS
The $200 million round is the latest evidence that surging interest in autoimmune disease cell therapies could expand to include developers of bispecific antibodies.
-
Permission granted by Bluebird bio
Bluebird, Vertex prep for first commercial use of sickle cell gene therapies
One patient has started the treatment process for Bluebird's Lyfgenia, while five others have done the same for Vertex's Casgevy.
Updated May 7, 2024 -
Mohammed Haneefa Nizamudeen via Getty Images
Gossamer sells rights to drug it hopes can rival a new Merck therapy
One analyst thinks the collaboration “bodes well” for Gossamer, which has had trouble convincing investors its drug seralutinib can compete on the market.
-
Christopher Furlong via Getty Images
AstraZeneca ups stake in Cellectis in latest cell therapy bet
The British drugmaker, which has made genetic medicine a larger priority of late, added $140 million to a deal to develop up to 10 gene and cell therapies.
-
Anna Moneymaker via Getty Images
As drug shortages reach record highs, regulators weigh next steps
With many chemotherapy and ADHD drugs stuck in stubbornly short supply, several agencies are looking for new solutions.
-
Novartis
Why selling to Novartis made sense for Mariana
Conversations at this year's J.P. Morgan Healthcare Conference led to a $1 billion buyout that Mariana's CEO described as a "perfect marriage."
-
Mario Tama via Getty Images
Obesity drugsAmgen shares soar as executives outline obesity drug push
The company said data for its Wegovy competitor was promising enough to move the drug into late-stage testing, triggering a stock jump that added billions to Amgen’s market value.
-
Permission granted by Nasdaq, Inc.
CG follows big IPO with new results for bladder cancer drug
Newly disclosed Phase 3 results presented Friday match findings the biotech disclosed last year, while offering a more comprehensive look at how its drug stacks up to rival therapies.
